Editors: Rivas L, Gil C.
Royal Society of Chemistry, 2017.
Summary: This book aims to provide a perspective of the current treatments for leishmaniasis and their challenges, blended with the emerging strategies and methodologies that will drive new target appraisals and drug developments, as well as addressing the molecular basis of resistance in Leishmania.
Chapters with DNDi co-authors:
Leishmaniasis, impact ,and therapeutic needs
by Alvar J, Arana B. Drug discovery for leishmaniasis 2017, doi: 10.1039/9781788010177-00001
Anti-leishmanial drug discovery: Past, present, and future perspectives
by Mowbray CE. Drug discovery for leishmaniasis 2017, doi: 10.1039/9781788010177-00024
From bench to bedside: Development and optimization of clinical therapies for visceral leishmaniasis
by Alves F, Gillon JY, Arana B, Dorlo TPC. Drug discovery for leishmaniasis 2017, doi: 10.1039/9781788010177-00037
